Hypermarcas (OTCMKTS:HYPMY) Shares Gap Down - Here's Why

Key Points

• Hypermarcas' stock price gapped down from $4.60 to $4.35 prior to trading on Wednesday, with a trading volume of 378 shares.
• Scotiabank upgraded Hypermarcas to a "strong-buy" rating, contributing to an average rating of "Strong Buy" among analysts.
• The company reported a quarterly earnings per share of $0.12 and has a market capitalization of $2.76 billion.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $4.60, but opened at $4.35. Hypermarcas shares last traded at $4.35, with a volume of 378 shares.

Analyst Upgrades and Downgrades

Separately, Scotiabank upgraded Hypermarcas to a "strong-buy" rating in a research report on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Strong Buy".

Hypermarcas Stock Down 5.4%

The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $2.76 billion, a P/E ratio of 20.72 and a beta of 0.86. The firm has a 50 day simple moving average of $4.44 and a two-hundred day simple moving average of $4.21.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.12 earnings per share for the quarter. Hypermarcas had a return on equity of 6.19% and a net margin of 11.28%.

About Hypermarcas

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.